Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, TPA (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients, and the reversal of physical disabilities resulting from stroke. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the work of two scientists, Prof. Richard Chang and Prof. Zhang Tao Han. Both have conducted research on TPA for many years and have become experts in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us
Rich Pharmaceuticals Inc. has been licensed to pursue the clinical development of their lead drug, TPA, in acute myelogenous leukemia (AML) and stroke.
Rich Pharmaceuticals appoints Robert Thomas as COO View Press Release
Rich Pharmaceuticals appoints David Chou, Phd. to the Board of Director View Press Release